Clinical guidelines and protocols

Only 58% of EMA-approved drug indications from 2011 to 2024 had at least one trial population tested against an appropriate comparator. The share fell from 78% of 2011 to 2012 approvals to 39% of 2023 to 2024 approvals. #SyenzaNews #MarketAccess

"The American Cancer Society has updated its prostate cancer screening guideline, with regular PSA testing for average-risk men aged 50 to 69." #SyenzaNews #ProstateCancer

The Enzutrix patent dispute goes to South Africa's Constitutional Court on 23 November 2026. UC and Astellas are pursuing damages over the generic prostate cancer drug, while Eurolab argues the patent was never validly obtained. #SyenzaNews #MarketAccess

A Congressional Research Service sidebar maps the state lawsuits over AI in health care, from insurer claim denials to wellness apps and chatbots.

A Mayo Clinic cardiologist's TV-set question makes the case for a home blood pressure monitor, with a caution on device reliability and home data in the chart.

The Ministry of Food and Drug Safety hosts ICMRA, the international coalition of medicines regulators, in Seoul from 3 to 6 November 2026, with AI rules and alternatives to animal testing on the agenda. #SyenzaNews #MarketAccess #drugregulation

The FDA has launched the Neuroscience Advancement and Innovation Nexus, starting with an Alzheimer's Prevention Accelerator. #SyenzaNews #Alzheimers #MarketAccess

A new npj Digital Medicine article in press from SCPMG proposes the C-TACT clinical AI governance framework, with weighted lifecycle scorecards and its limits stated.

How can AI-powered scheduling transform operating room efficiency and deliver major cost savings? Recent advancements are enabling hospitals to optimize resource allocation, reduce cancellations, and streamline workflows through intelligent automation. Discover how this technology is reshaping surgical operations and improving financial outcomes. #SyenzaNews #AIinHealthcare #HealthcareInnovation #ai #DigitalTransformation

What steps is the FDA taking to accelerate rare disease treatments? The FDA’s new Rare Disease Framework Initiative aims to streamline regulatory pathways, enhance collaboration with sponsors, and improve patient access to innovative therapies. Explore how this could reshape drug development for underserved patient populations. #SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #healthcarepolicy

OHE's A Dose of Economics explores why medicines made for one patient challenge regulation, payment and HTA.

AI is entering every stage of medical training. A new npj Digital Medicine Perspective maps how to integrate it responsibly across UGME, GME and CME.